Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bristol-Myers Squibb (1BMY) Stock Price & Analysis

1BMY Stock Chart & Stats

€56.24€1.92(3.53%)
At close: 5:30 PM GMT+1
€52.5€55€57.53 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 55.82 - EUR 56.77
52-Week Range
EUR 35.00 - EUR 84.00
Previous Close
EUR 54.32
Volume
158
Average Volume (3M)
68
Market Cap
EUR 114.36B
Enterprise Value
EUR 160.34B
Total Cash (Recent Filing)
EUR 12.58B
Total Debt (Recent Filing)
EUR 44.81B
Price to Earnings (P/E)
13.8
Beta
0.21
Next Earnings
Feb 04, 2027 (Est.)
EPS Estimate
1.36
Next Dividend Ex-Date
N/A
Dividend Yield
3.96%

Bulls Say, Bears Say

Bulls Say

Diversified Growth Portfolio

A broad set of commercially meaningful medicines reduces reliance on any single product and supports more durable revenue expansion. The portfolio’s double-digit growth and multiple billion-dollar contributors provide a stronger base for absorbing individual product declines while funding continued innovation.

Pipeline And Product Expansion

Recent approvals and positive late-stage results strengthen the pathway for portfolio renewal beyond existing franchises. Multiple therapeutic areas and development programs provide several potential sources of future growth, helping offset mature-product pressure if execution and regulatory progress continue.

Strong Cash Generation And Efficiency

Substantial liquidity and quarterly operating cash generation give BMS capacity to support research, manufacturing investment, business development, and shareholder commitments. The planned productivity initiative adds a further structural support by targeting $2 billion of efficiencies by the end of 2027.

Bears Say

Eliquis Exclusivity Loss

Eliquis is a major franchise, so the expected post-exclusivity decline creates a material revenue gap that the newer portfolio must replace. Even with continued U.S. growth, this transition can pressure earnings visibility and increase dependence on successful launches and pipeline execution.

Elevated Leverage

The elevated debt burden can constrain capital allocation as BMS manages product investment, business development, dividends, and upcoming franchise transitions. Higher leverage also leaves less flexibility to absorb weaker earnings or fund opportunities if operating performance becomes more volatile.

Clinical Program And Launch Execution Risk

The Zolacel pause delays potential pipeline contribution and introduces meaningful safety and regulatory uncertainty around an otherwise promising autoimmune platform. Restart requirements and authority review could consume resources, extend timelines, and reduce the near-term contribution expected from this program.

Bristol-Myers Squibb News

1BMY FAQ

What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €35.00 and its highest was €84.00 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is €114.36B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s next earnings report is estimated for Feb 04, 2027 (not yet confirmed), which is in 94 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 29, 2026. The company reported €1.209 earnings per share for the quarter, beating the consensus estimate of €0.984 by €0.225.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.36.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,044,085,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.209 in its last earnings report, beating expectations of €0.984. Following the earnings report the stock price went up 0.111%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Hedge funds hold Bristol-Myers Squibb shares: the largest hedge-fund position in Bristol-Myers Squibb is 1,970,825,339 shares, and hedge funds decreased their holdings by 4.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology